NCT01519817 is a Phase 1 clinical trial of GI-6301 (Yeast Brachyury Vaccine) in Neoplasms, sponsored by National Cancer Institute (NCI).

Who is sponsoring NCT01519817?

NCT01519817 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT01519817?

Interventions in NCT01519817: GI-6301 (Yeast Brachyury Vaccine).

What condition does NCT01519817 study?

NCT01519817 studies Neoplasms, Malignant Solid Tumors, Colon Neoplasms, Adenocarcinoma.

Is NCT01519817 still recruiting?

NCT01519817 is currently completed. Last updated 29 January 2018.

Are results published for NCT01519817?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-01-29 · How we verify

NCT01519817

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cancer Vaccine Targeting Brachyury Protein in Tumors

Completed Phase 1 Results posted Last updated 29 January 2018

What this trial tests

Phase 1 trial testing GI-6301 (Yeast Brachyury Vaccine) in Neoplasms in 34 participants. Completed in 1 September 2016.

Timeline

5 January 2012

Primary endpoint
3 March 2016

1 September 2016

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	5 January 2012
Primary completion	3 March 2016
Estimated completion	1 September 2016
Sites	1 location across United States

Drugs / interventions tested

GI-6301 (Yeast Brachyury Vaccine) — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →
Malignant Solid Tumors — all drugs for Malignant Solid Tumors →
Colon Neoplasms — all drugs for Colon Neoplasms →
Adenocarcinoma — all drugs for Adenocarcinoma →

Sponsor

National Cancer Institute (NCI)

Who can join

Adults 18 to 100, any sex, with Neoplasms or Malignant Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Brachyury-Specific T-cell Responses Primary · Baseline (pre-vaccination) and approximately day 84 (after 6 vaccinations)

A fluorescense activated cell sorting (FACS)-based assay for cluster of differentiation 4 (CD4) or cluster of differentiation 8 (CD8) T-cells expressing the cytokines interferon (IFN) gamma, interleukin 2 (IL2), and tumor necrosis factor (TNF) alpha, and/or cluster of differentiation 107a (CD107a) (a marker for lytic potential) was used to determine the numbers of participants showing development or enhancement of the level of brachyury-specific T-cells after vaccination.

CD107a + CD4 T-cell response

Group	Value	95% CI
4 YU (Dose Level 1)	1
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	4
80 YU (Dose Level 4)	1

IFN gamma + CD4 T-cell response

Group	Value	95% CI
4 YU (Dose Level 1)	1
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	3
80 YU (Dose Level 4)	2

IL2 + CD4 T-cell response

Group	Value	95% CI
4 YU (Dose Level 1)	0
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	3
80 YU (Dose Level 4)	3

TNF alpha + CD4 T-cell response

Group	Value	95% CI
4 YU (Dose Level 1)	0
16 YU (Dose Level 2)	1
40 YU (Dose Level 3)	6
80 YU (Dose Level 4)	2

CD107a + CD8 T-cell response

Group	Value	95% CI
4 YU (Dose Level 1)	0
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	3
80 YU (Dose Level 4)	4

IFN gamma + CD8 T-cell response

Group	Value	95% CI
4 YU (Dose Level 1)	0
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	3
80 YU (Dose Level 4)	2

IL2 + CD8 T-cell response

Group	Value	95% CI
4 YU (Dose Level 1)	0
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	0
80 YU (Dose Level 4)	1

TNF alpha + CD8 T-cell response

Group	Value	95% CI
4 YU (Dose Level 1)	0
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	2
80 YU (Dose Level 4)	3

Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine Primary · 4 years and 25 days

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one o

Group	Value	95% CI
4 YU (Dose Level 1)	4
16 YU (Dose Level 2)	3
40 YU (Dose Level 3)	16
80 YU (Dose Level 4)	10

Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) Secondary · 3 and 5 months restaging

Clinical benefit is defined as partial response (PR) or stable disease (SD) and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial response is ≥30% decrease in the sum of greatest diameters/no new lesions. Progressive disease is ≥20% increase in the sum of greatest diameters/new lesions. Stable disease does not meet criteria for complete response (disappearance of all lesions; no new lesions), partial response, or progressive disease.

Stable disease at 3 months

Group	Value	95% CI
4 YU (Dose Level 1)	3
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	8
80 YU (Dose Level 4)	6

Stable disease at 5 months

Group	Value	95% CI
4 YU (Dose Level 1)	2
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	4
80 YU (Dose Level 4)	3

Partial response at 3 months

Group	Value	95% CI
4 YU (Dose Level 1)	0
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	0
80 YU (Dose Level 4)	0

Partial response at 5 months

Group	Value	95% CI
4 YU (Dose Level 1)	0
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	1
80 YU (Dose Level 4)	0

Progressive disease at 3 months

Group	Value	95% CI
4 YU (Dose Level 1)	1
16 YU (Dose Level 2)	3
40 YU (Dose Level 3)	8
80 YU (Dose Level 4)	5

Progressive disease at 5 months

Group	Value	95% CI
4 YU (Dose Level 1)	1
16 YU (Dose Level 2)	0
40 YU (Dose Level 3)	3
80 YU (Dose Level 4)	0

Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) Secondary · Pre (Baseline) and Day 85 after 6 vaccinations

Blood samples will be collected via apheresis and analyzed by multicolor flow cytometry in PBMCs for cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), Natural Killer (NK), Natural Killer T (NKT), conventional dendritic cell (cDC), plasmacytoid dendritic cell (pDC), myeloid-derived suppressor cell (MDSC), Tregs, CD4 central memory (CD4 CM), CD4 effector memory (CD4 EM), CD4 terminal effector memory (CD4 EMRA), CD4 naïve, CD8 CM, CD8 EM, CD8 EMRA, and CD8 naïve cells. Significance of changes in immune cells was determined by p value (Wilcoxon test) and the median and interq

Median CD4 Pre

Group	Value	95% CI
4 YU (Dose Level 1)	37.70	24.11 – 46.36
16 YU (Dose Level 2)	43.57	40.26 – 46.87
40 YU (Dose Level 3)	29.30	24.65 – 39.77
80 YU (Dose Level 4)	33.58	26.84 – 39.92

Median CD4 d85

Group	Value	95% CI
4 YU (Dose Level 1)	38.61	24.44 – 47.73
16 YU (Dose Level 2)	33.44	33.37 – 33.52
40 YU (Dose Level 3)	34.29	25.56 – 37.44
80 YU (Dose Level 4)	27.99	25.85 – 39.38

Median CD8 Pre

Group	Value	95% CI
4 YU (Dose Level 1)	15.87	8.26 – 16.86
16 YU (Dose Level 2)	14.77	3.49 – 26.04
40 YU (Dose Level 3)	15.96	10.76 – 19.48
80 YU (Dose Level 4)	13.76	10.31 – 19.77

Median CD8 d85

Group	Value	95% CI
4 YU (Dose Level 1)	15.67	9.102 – 16.57
16 YU (Dose Level 2)	13.63	4.123 – 23.14
40 YU (Dose Level 3)	15.42	10.96 – 22.44
80 YU (Dose Level 4)	16.02	10.57 – 25.5

Median B cells Pre

Group	Value	95% CI
4 YU (Dose Level 1)	7.05	6.19 – 10.07
16 YU (Dose Level 2)	11.02	9.92 – 12.11
40 YU (Dose Level 3)	8.97	3.54 – 12.13
80 YU (Dose Level 4)	7.82	3.13 – 12.07

Median B cells d85

Group	Value	95% CI
4 YU (Dose Level 1)	6.93	6.16 – 10.58
16 YU (Dose Level 2)	9.78	7.95 – 11.62
40 YU (Dose Level 3)	9.10	5.07 – 12.17
80 YU (Dose Level 4)	8.77	3.78 – 10.72

Median Natural Killer (NK) Pre

Group	Value	95% CI
4 YU (Dose Level 1)	5.21	4.14 – 6.94
16 YU (Dose Level 2)	6.57	3.27 – 9.87
40 YU (Dose Level 3)	5.72	3.13 – 8.51
80 YU (Dose Level 4)	5.89	4.59 – 9.14

Median Natural Killer (NK) d85

Group	Value	95% CI
4 YU (Dose Level 1)	5.72	4.03 – 7.39
16 YU (Dose Level 2)	8.41	5.50 – 11.31
40 YU (Dose Level 3)	4.22	3.97 – 10.07
80 YU (Dose Level 4)	9.14	5.95 – 11.4

Changes in Serum Levels of Cytokines Secondary · Pre (Baseline) and Day 85 after 6 vaccinations

Blood samples were collected and changes in serum levels of cytokines interferon gamma (IFNg), Interleukin 10 (IL-10), Interleukin 12 (IL-12)p70, Interleukin 1b (IL-1b), Interleukin 2 (IL-2), Interleukin 6 (IL-6), Interleukin 8 (IL-8), and tumor necrosis factor (TNF) were assessed by the multiplexed mesoscale assay. Significance of changes in serum levels of cytokines was determined by p value (Wilcoxon test) and the median and interquartile range of data.

Median IFNg Pre

Group	Value	95% CI
4 YU (Dose Level 1)	3.63	2.47 – 6.12
16 YU (Dose Level 2)	3.56	2.99 – 4.13
40 YU (Dose Level 3)	2.805	1.97 – 3.6
80 YU (Dose Level 4)	4.47	4.05 – 7.48

Median IFNg d85

Group	Value	95% CI
4 YU (Dose Level 1)	2.64	2.17 – 3.17
16 YU (Dose Level 2)	2.83	2.62 – 3.04
40 YU (Dose Level 3)	2.84	1.76 – 4.71
80 YU (Dose Level 4)	4.9	2.91 – 6.81

Median IL-10 Pre

Group	Value	95% CI
4 YU (Dose Level 1)	0.24	0.17 – 0.54
16 YU (Dose Level 2)	0.215	0.2 – 0.23
40 YU (Dose Level 3)	0.21	0.17 – 0.28
80 YU (Dose Level 4)	0.4	0.31 – 0.47

Median IL-10 d85

Group	Value	95% CI
4 YU (Dose Level 1)	0.26	0.23 – 0.39
16 YU (Dose Level 2)	0.285	0.28 – 0.29
40 YU (Dose Level 3)	0.24	0.18 – 0.31
80 YU (Dose Level 4)	0.4	0.26 – 0.52

Median IL-12p70 Pre

Group	Value	95% CI
4 YU (Dose Level 1)	0.2	0.2 – 0.22
16 YU (Dose Level 2)	0.22	0.2 – 0.24
40 YU (Dose Level 3)	0.2	0.2 – 0.2
80 YU (Dose Level 4)	0.2	0.2 – 0.37

Median IL-12p70 d85

Group	Value	95% CI
4 YU (Dose Level 1)	0.2	0.2 – 0.28
16 YU (Dose Level 2)	0.2	0.2 – 0.2
40 YU (Dose Level 3)	0.2	0.2 – 0.2
80 YU (Dose Level 4)	0.2	0.2 – 0.26

Median IL-1b Pre

Group	Value	95% CI
4 YU (Dose Level 1)	0.24	0.24 – 1.15
16 YU (Dose Level 2)	0.24	0.24 – 0.24
40 YU (Dose Level 3)	0.24	0.24 – 0.24
80 YU (Dose Level 4)	0.24	0.24 – 2.52

Median IL-1b d85

Group	Value	95% CI
4 YU (Dose Level 1)	0.24	0.24 – 0.25
16 YU (Dose Level 2)	0.24	0.24 – 0.24
40 YU (Dose Level 3)	0.24	0.24 – 0.24
80 YU (Dose Level 4)	0.24	0.24 – 0.89

Changes in Soluble Cluster of Differentiation 27 (sCD27) Secondary · Pre (Baseline) and Day 85 after 6 vaccinations

Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27 was determined by p value (Wilcoxon test) and the median and interquartile range of data.

Median sCD27 Pre

Group	Value	95% CI
4 YU (Dose Level 1)	99.07	91.13 – 131
16 YU (Dose Level 2)	98.63	87.12 – 110.1
40 YU (Dose Level 3)	97.47	85.15 – 110.9
80 YU (Dose Level 4)	128.4	123.9 – 145.6

Median sCD27 d85

Group	Value	95% CI
4 YU (Dose Level 1)	97.17	92.07 – 1112
16 YU (Dose Level 2)	92.07	83.3 – 100.8
40 YU (Dose Level 3)	101.7	98.85 – 105.1
80 YU (Dose Level 4)	133.1	129.7 – 155.8

Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) Secondary · Pre (Baseline) and Day 85 after 6 vaccinations

Blood samples were collected and changes in serum levels of the ratio of soluble sCD27:sCD40L was assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27:sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.

Median sCD27:sCD40L Pre

Group	Value	95% CI
4 YU (Dose Level 1)	5.982	5.71 – 11.67
16 YU (Dose Level 2)	9.57	7.88 – 11.26
40 YU (Dose Level 3)	9.571	7.67 – 19.89
80 YU (Dose Level 4)	8.57	6.93 – 10.62

Median sCD27:sCD40L d85

Group	Value	95% CI
4 YU (Dose Level 1)	6.428	4.79 – 9.43
16 YU (Dose Level 2)	8.294	7.29 – 9.29
40 YU (Dose Level 3)	10.47	6.63 – 19.38
80 YU (Dose Level 4)	8.257	6.96 – 8.91

Changes in Soluble Cluster of Differentiation 40L (sCD40L) Secondary · Pre (Baseline) and Day 85 after 6 vaccinations

Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.

Median sCD40L Pre

Group	Value	95% CI
4 YU (Dose Level 1)	15.3	11.39 – 17.99
16 YU (Dose Level 2)	10.24	9.78 – 11.06
40 YU (Dose Level 3)	9.648	5.27 – 13.99
80 YU (Dose Level 4)	14.72	13.67 – 18.74

Median sCD40L d85

Group	Value	95% CI
4 YU (Dose Level 1)	15.23	11.96 – 19.42
16 YU (Dose Level 2)	11.14	10.84 – 11.43
40 YU (Dose Level 3)	9.854	5.86 – 14.52
80 YU (Dose Level 4)	18.57	16.09 – 19.51

Adverse events — posted to ClinicalTrials.gov

Time frame: 4 years and 25 days. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

4 YU (Dose Level 1)

Serious: 0/4 (0%)

Deaths: 0/4

16 YU (Dose Level 2)

Serious: 0/3 (0%)

Deaths: 0/3

40 YU (Dose Level 3)

Serious: 5/16 (31%)

Deaths: 0/16

80 YU (Dose Level 4)

Serious: 6/11 (55%)

Deaths: 0/11

Serious adverse events (19 terms)

Reaction	System	4 YU (Dose Level 1)	16 YU (Dose Level 2)	40 YU (Dose Level 3)	80 YU (Dose Level 4)
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—
Aortic valve disease	Cardiac disorders	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—
Chest wall pain	Musculoskeletal and connective tissue disorders	—	—	—	—
Hyperglycemia	Metabolism and nutrition disorders	—	—	—	—
Urinary tract obstruction	Renal and urinary disorders	—	—	—	—
Wound infection	Infections and infestations	—	—	—	—
Atelectasis	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Bone infection	Infections and infestations	—	—	—	—
Cholecystitis	Hepatobiliary disorders	—	—	—	—
Eye infection	Eye disorders	—	—	—	—
Fatigue	General disorders	—	—	—	—
Lung infection	Infections and infestations	—	—	—	—
Respiratory, thoracic and mediastinal disorders - Other, lung obstruction	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Soft tissue infection	Infections and infestations	—	—	—	—
Upper respiratory infection	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Urinary tract infection	Renal and urinary disorders	—	—	—	—
Wheezing	Respiratory, thoracic and mediastinal disorders	—	—	—	—

Other adverse events (125 terms — click to expand)

Reaction	System	4 YU (Dose Level 1)	16 YU (Dose Level 2)	40 YU (Dose Level 3)	80 YU (Dose Level 4)
Anemia	Blood and lymphatic system disorders	—	—	—	—
Injection site reaction	Skin and subcutaneous tissue disorders	—	—	—	—
Injection site reaction	General disorders	—	—	—	—
Hyperglycemia	Metabolism and nutrition disorders	—	—	—	—
Hypophosphatemia	Metabolism and nutrition disorders	—	—	—	—
White blood cell decreased	Investigations	—	—	—	—
Alkaline phosphatase increased	Investigations	—	—	—	—
Fatigue	General disorders	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—
Lymphocyte count decreased	Investigations	—	—	—	—
Pain	General disorders	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—
Proteinuria	Renal and urinary disorders	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Creatinine increased	Investigations	—	—	—	—
Headache	Nervous system disorders	—	—	—	—
Hemoglobinuria	Renal and urinary disorders	—	—	—	—
Hyponatremia	Metabolism and nutrition disorders	—	—	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Diarrhea	Gastrointestinal disorders	—	—	—	—
Hypoalbuminemia	Metabolism and nutrition disorders	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—
Fever	General disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Weight loss	Investigations	—	—	—	—
Dyspnea	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Fever	General disorders	—	—	—	—
Hypercalcemia	Metabolism and nutrition disorders	—	—	—	—
Hypernatremia	Metabolism and nutrition disorders	—	—	—	—
Hypoglycemia	Metabolism and nutrition disorders	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—
Rhinitis infective	Infections and infestations	—	—	—	—
Fracture	Injury, poisoning and procedural complications	—	—	—	—
Conjunctivitis	Eye disorders	—	—	—	—
Cystitis noninfective	Renal and urinary disorders	—	—	—	—
Edema face	General disorders	—	—	—	—
Edema limbs	General disorders	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—
Flu like symptoms	General disorders	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—

Most-reported serious reactions: Small intestinal obstruction, Abdominal pain, Aortic valve disease, Atrial fibrillation, Chest wall pain, Hyperglycemia, Urinary tract obstruction, Wound infection.

Data from ClinicalTrials.gov NCT01519817 adverse events section.

Sponsor's own description

Background: \- Cancer vaccines are being developed to help teach the body's immune system to attack and destroy cancer cells. A new vaccine being tested targets Brachyury protein. This protein is present in some tumor cells, and it can help tumor cells spread to other parts of the body. Researchers want to see whether the new Brachyury protein vaccine can help treat people with advanced carcinomas. Objectives: \- To test the safety and effectiveness of a cancer vaccine that targets Brachyury protein in tumor cells. Eligibility: * Individuals at least 18 years of age who have advanced cancers that have not responded or are no longer responding to standard treatments. * Because the vaccine is made with yeast, people with yeast allergies will not be eligible. Design: * Participants will be screened with a medical history and physical exam. Imaging studies will be used to examine the cancer. Heart and thyroid function tests will be conducted. Blood and urine samples will also be collected. * Participants will receive vaccine injections every 2 weeks, for a total of seven visits. After seven visits, if the cancer has shrunk or stopped growing, participants will continue to have the vaccine about once a month. * Treatment will be monitored with frequent blood tests and imaging studies. Other tests will be given as directed by the study doctors. Some participants will have apheresis to collect additional blood cells for study. * Participants will continue to receive the vaccine as long the tumor does not start growing again and there are no serious side effects....

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer vaccines as promising immuno-therapeutics: platforms and current progress.
Liu J, Fu M, Wang M, Wan D, et al · · 2022 · cited 497× · PMID 35303904 · DOI 10.1186/s13045-022-01247-x
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.
Heery CR, Singh BH, Rauckhorst M, Marté JL, et al · · 2015 · cited 99× · PMID 26130065 · DOI 10.1158/2326-6066.cir-15-0119
Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
Nouri M, Ratther E, Stylianou N, Nelson CC, et al · · 2014 · cited 63× · PMID 25566507 · DOI 10.3389/fonc.2014.00370
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.
DeMaria PJ, Bilusic M, Park DM, Heery CR, et al · · 2021 · cited 45× · PMID 33594772 · DOI 10.1002/onco.13720
Colorectal cancer vaccines: The current scenario and future prospects.
Jia W, Zhang T, Huang H, Feng H, et al · · 2022 · cited 33× · PMID 35990683 · DOI 10.3389/fimmu.2022.942235
Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.
Malek R, Wang H, Taparra K, Tran PT. · · 2017 · cited 33× · PMID 28214899 · DOI 10.1159/000447238
Chordoma: The Quest for Better Treatment Options.
Heery CR. · · 2016 · cited 29× · PMID 28261639 · DOI 10.1007/s40487-016-0016-0
Trial watch: Naked and vectored DNA-based anticancer vaccines.
Bloy N, Buqué A, Aranda F, Castoldi F, et al · · 2015 · cited 29× · PMID 26155408 · DOI 10.1080/2162402x.2015.1026531

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01519817 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 29 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01519817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing